Introduction
============

Osteosarcoma is the most common primary bone malignancy in children and adolescents ([@b1-ol-0-0-8032]), which usually occurs in the metaphyseal region of tubular long bones ([@b2-ol-0-0-8032]). Although numerous modern therapies, including surgery, chemotherapy and radiotherapy have been used for treating osteosarcoma, the 5-year survival rate of patients with osteosarcoma is 60--70% ([@b3-ol-0-0-8032]). With the improvements in treatment techniques, the mortality rate of osteosarcoma is decreasing at \~1.3% per year ([@b4-ol-0-0-8032]). However, the etiology of osteosarcoma is unclear. Therefore, identification of the key genes associated with osteosarcoma is important for treatment of the disease.

As a type of plant polyphenol, curcumin is extracted from *Curcuma longa* ([@b5-ol-0-0-8032]) and exhibits anti-tumor, anti-inflammatory, antioxidant and anticoagulation capacities ([@b6-ol-0-0-8032]--[@b9-ol-0-0-8032]). Previous studies have demonstrated that curcumin serves functions in the progression of a number of types of cancer, including osteosarcoma ([@b10-ol-0-0-8032]), pancreatic cancer ([@b11-ol-0-0-8032]) and colon cancer ([@b12-ol-0-0-8032]). Fossey *et al* ([@b13-ol-0-0-8032]) revealed that FLLL32, a novel compound obtained from curcumin, inhibited signal transducers and activators of transcription 3 (*STAT3*) and induced apoptosis in osteosarcoma. Chang *et al* ([@b14-ol-0-0-8032]) indicated that curcumin induced apoptosis in the osteosarcoma MG63 cell line via mediating the reactive oxygen species/cytochrome c/caspase-3 pathway. Leow *et al* ([@b15-ol-0-0-8032]) demonstrated that curcumin and PKF118-310 may delay tumorigenesis and metastasis of osteosarcoma through inhibiting the Wnt/β-catenin signaling pathway. Taken together, these studies indicate that curcumin exhibits an effect on the pathogenesis of osteosarcoma through different pathways. Despite these aforementioned data, the target genes of curcumin in osteosarcoma remain unclear.

RNA sequencing (RNA-seq), which is based on deep-sequencing technology, is a more developed approach compared with transcriptome profiling ([@b16-ol-0-0-8032]). Several developments in RNA-seq, including mapping of the transcription start site, characterization of small RNA and detection of strand-specific, gene fusion and alternative splicing events, have been identified ([@b17-ol-0-0-8032]). In the present study, RNA-seq data analysis was performed on human osteosarcoma U-2 OS cells, which were treated by curcumin or dimethyl sulfoxide (DMSO). Differentially expressed genes (DEGs) between the curcumin-treated and control groups were identified, and the functions of the DEGs were predicted by functional and pathway enrichment analyses. A protein-protein interaction (PPI) network involving the DEGs was also constructed to additionally determine the target genes of curcumin in osteosarcoma. In addition, the mRNA levels of the top 10 nodes in the PPI network were confirmed, and it was identified that the mRNA levels of clathrin heavy chain (*CLTC*) and inositol 1,4,5-triphosphate receptor type 1 (*ITPR1*) in curcumin-treated cells were significantly increased. In addition, the effects of curcumin and *ITPR1* on proliferation, apoptosis, migration and invasion in human osteosarcoma U-2 OS cells were investigated.

Materials and methods
=====================

### Cell cultivation and curcumin treatment

The human osteosarcoma U-2 OS cell line was purchased from Cell Bank of Chinese Academy of Sciences (Shanghai, China). The U-2 OS cells were inoculated in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.) and cultured at 37°C in a 5% CO~2~ incubator (Thermo Fisher Scientific, Inc.). When the passaged cells reached 80--90% confluence, the cells were digested using pancreatin (Gibco; Thermo Fisher Scientific, Inc.). The digested cells were centrifuged at 1,000 × g and 4°C for 5 min, and then supernatant was discarded. Subsequently, the cells were preserved in frozen stock solution containing 10% DMSO (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 40% FBS and 50% RPMI-1640 medium, and stored in program frozen box.

The U-2 OS cells were seeded in 6-well plates (2×10^6^ cell/well) and incubated in 5 ml serum-free medium in a 5% CO~2~ incubator (Thermo Fisher Scientific, Inc.) at 37°C overnight. Curcumin (Sigma-Aldrich; Merck KGaA, 15 µmol/l) was dissolved in DMSO. Subsequently, U-2 OS cells were treated with 15 µM curcumin at 37°C in a 5% CO~2~ incubator for 48 h (curcumin group). Concurrently, in the control groups, U-2 OS cells were treated with an equal volume of DMSO. Finally, the cells were washed twice with cold PBS.

All studies were approved by the Scientific and Ethical Committee of the 309th Hospital of Chinese People\'s Liberation Army (Beijing, China) and performed in accordance with the ethical standards.

### RNA sequencing data

Total RNA was isolated from the U-2 OS cells using TRIzol^®^ (Takara Bio, Inc., Otsu, Japan) according to the manufacturer\'s protocol and quantified by spectrophotometry. Then, a transcriptome library was constructed using NEBNext^®^ Ultra™ RNA Library Prep kit for Illumina^®^ (cat. no. E7530; New England Biolabs, Inc., Ipswich, MA, USA) following the manufacturer\'s protocol. RNA was separated into RNA fragments (\~200 nt), followed by double-stranded cDNA being synthesized and end-repaired. Then, adaptor ligation and polymerase chain reaction (PCR) enrichment (denaturation step: 98°C for 30 sec; 12 cycles: 98°C for 10 sec and annealing temperature 65°C for 75 sec; final extension step: 65°C for 5 min) were performed using the primers and reagents supplied with the NEBNext^®^ Ultra RNA Library Prep kit. The quality of the library was analyzed using Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA), and RNA was sequenced on Hiseq 2500 (Illumina, Inc., San Diego, CA, USA).

### Data quality control and screening of DEGs

Subsequent to quality controls of the reads, they were mapped to the reference human genome (hg19) using TopHat ([@b18-ol-0-0-8032]) and assembled by Bowtie 1 software ([@b19-ol-0-0-8032]). Combined with sequence alignment results from TopHat and hg19 annotation information downloaded from the University of California, Santa Cruz (UCSC) database (<https://www.astro.ucsc.edu/>) ([@b20-ol-0-0-8032]), the DEGs between curcumin and control groups were identified using Cufflink software ([@b21-ol-0-0-8032]). P\<0.01 and \|log~2~ fold change (FC)\| ≥1 were set as cut-off criteria.

### Functional and pathway enrichment analysis

Gene Ontology (GO, <http://geneontology.org/>) analysis develops a series of controlled and structured vocabularies for annotating functions of genes and their products ([@b22-ol-0-0-8032]). The Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.kegg.jp/>) is a biological database, which stores genomic, chemical and systemic functional information ([@b23-ol-0-0-8032]). Using the cluster profiler ([@b24-ol-0-0-8032]) package in R, GO functional and KEGG pathway enrichment analyses were performed for upregulated and downregulated genes, respectively. The raw P-value was adjusted by the Benjamini-Hochberg method ([@b25-ol-0-0-8032]), and the adjusted P-value (also known as false discovery rate, FDR) \<0.05 was used as a threshold.

### Construction of PPI network

Human Protein Reference Database (HPRD) includes curated proteomic information and describes human PPIs ([@b26-ol-0-0-8032]). Using HPRD Release 9 (<http://www.hprd.org/query>) ([@b26-ol-0-0-8032]), pairs of interacting human proteins were downloaded, and the self-interacting protein pairs were removed. The DEGs were mapped with the downloaded PPI pairs, and those pairs involving the identified DEGs were extracted. Finally, the PPI network was visualized using Cytoscape software (version 2.8.0; [www.cytoscape.org](www.cytoscape.org)) and named as the DEG PPI network ([@b27-ol-0-0-8032]). Proteins are represented by nodes, the degree is the number of nodes which interact with the node in question, and the higher the degree the more important the protein in the PPI network.

### Quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis

The cells treated with curcumin were dissolved in TRIzol^®^ reagent (Takara Bio, Inc.) for extraction of total RNA. Primers for key genes are summarized in [Table I](#tI-ol-0-0-8032){ref-type="table"}. Using SYBR^®^ Premix Ex Taq™ (Applied Biosystems; Thermo Fisher Scientific, Inc.), RT-qPCR amplification was performed according to the following thermocycling conditions: 50°C for 3 min, 95°C for 3 min, followed by 40 cycles of 95°C for 10 sec and 58°C for 30 sec. Gene expression was quantified and calculated by the comparative threshold (Cq) cycle method (2^−ΔΔCq^) ([@b28-ol-0-0-8032]).

### RNA interference assay

The cells in the siRNA group were digested by pancreatin at 37°C for 5 min, and then complete medium was added to neutralize the pancreatin. Subsequently, the cells were centrifuged at 1,000 × g for 5 min at 4°C, and the supernatant was discarded. Subsequent to being counted, the cells were seeded in 6-well plates (8×10^5^ cell/well) and cultured in 2 ml antibiotic-free complete medium in a 5% CO~2~ incubator (Thermo Fisher Scientific, Inc.) at 3°C overnight. The ITPR1 small interfering (siRNA) were synthesized with the forward, 5′-AGACAGAAAACAGGAAAUUTT-3′ and reverse primer, (5′-AAUUUCCUGUUUUCUGUCUCA-3′). The ITPR1 siRNA (final concentration, 66 nM/l) and Lipofectamine^®^ 2000 reagent (1:25 vol/vol; Invitrogen; Thermo Fisher Scientific, Inc.) diluted with Opti-MEM medium (Gibco; Thermo Fisher Scientific, Inc.) were mixed and allowed to rest for 20 min. Subsequently, the cells were added to the siRNA mixture (500 µl/well) and Opti-MEM medium was replaced with complete medium following transfection for 6 h at room temperature. In addition, the cells were cultivated in a 5% CO~2~ incubator (Thermo Fisher Scientific, Inc.) at 37°C for 48 h. The cells were then collected for RT-qPCR assay. The cells in the negative control group were treated with scrambled siRNA (final concentration, 66 nM/l) (Shanghai Biotend Biological Technology, Co., Ltd., Shanghai, China) as control and cultured like the cells in the siRNA group. The cells in the control group were treated without siRNA but otherwise culture the same as the cells in the siRNA group.

### Cell proliferation assay

Subsequent to being digested and counted, the cells were seeded in a 96-well plate (4×10^4^ cell/well) and cultured in 100 ml antibiotic-free RPMI-1640 medium supplemented with 10% FBS (both FBS; Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO~2~ incubator (Thermo Fisher Scientific, Inc.) at 37°C overnight. Then, the cells were separately transfected at room temperature with the siRNA mixture, negative control siRNA and Lipofectamine 2000 reagent (Invitrogen; ThermoFisher Scientific Inc.) for 6 h. Subsequent to treatment with curcumin (Sigma-Aldrich; Merck KGaA), the cells were incubated with cell counting kit-8 at 37°C (CCK8; 10 µl/well; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) for 2 h. Finally, the absorption values under 450 nm were measured using an Epoch^™^ Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) to calculate viability.

### Flow cytometry

The U-2 OS cells were digested and counted, followed by seeding in a 6-well plate (8×10^5^ cell/well) and cultivation in 2 ml antibiotic-free RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO~2~ at 37°C overnight. Following transfection at room temperature for 6 h, the cells were treated with curcumin. The cells were digested by pancreatin, washed by PBS and resuspended in 1X binding buffer (BD Biosciences, San Jose, CA, USA). Subsequently, 100 µl of the above solution was transferred to flow cytometry tube, and stained with 5 µl fluorescein is isothiocyanate-Annexin V (BD Biosciences) and 5 µl propidium iodide (50 µg/ml; BD Biosciences) in the dark for 15 min at 25°C. Additionally, 400 µl 1X binding buffer (BD Biosciences) was added prior to flow cytometry using FCS Express 4 (De Novo Software, Glendale, CA).

### Wound healing assay

Lines were drawn on the base of 6-well plate with an equal interval of \~0.5--1 cm. Then, the digested and counted cells were seeded in a 6-well plate (8×10^5^ cell/well) and cultured in 2 ml RPMI-1640 medium without serum (Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO~2~ at 37°C overnight. Then, the cells were separately transfected at room temperature with the siRNA mixture, negative control siRNA and Lipofectamine 2000 reagent (Invitrogen; Thermo Fisher Scientific Inc.) for 6 h. Afterwards, the cells were wound by drawing lines using a pipetting needle. After this, the cells were washed with PBS and then there were several channels on the surface of cultured cells. Subsequent to treatment with 15 µmol/l curcumin, images of movement of the cells were captured every 12 h and measured by Image-Pro Plus 6.0 software (Media Cybernetics Inc., Rockville, MD, USA).

### Transwell assay

Subsequent to dilution with PBS (1:3 dilution), 50 µl Matrigel (1 mg/ml; Corning Incorporated, Corning, NY, USA) was solidified in a 24-well polycarbonate membrane following standing for 1 h at 37°C and resuspended following addition of 200 µl RPMI-1640 without serum (Gibco; Thermo Fisher Scientific, Inc.). The cells in each well of cell petri dish were added with 600 µl 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and then were cultured in a 6-well plate (8×10^5^ cell/well) in 2 ml RPMI-1640 medium with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO~2~ at 37°C overnight. Following this, the transferred and treated cells were digested by pancreatin (Gibco: Thermo Fisher Scientific, Inc.) and cultivated in the upper wells (1×10^5^ cell/well) in a 5% CO~2~ incubator (Thermo Fisher Scientific. Inc.) at 37°C for 12 h. Finally, the liquids in upper wells were discarded, and the cells that had not passed through the membranes were wiped off. The cells were stained with 0.1% crystal violet staining at room temperature for 20 min and observed under an inverted light microscope in 3 fields of view at magnification, ×200 (Olympus Corporation, Tokyo, Japan).

### Statistical analysis

Using SPSS 12.0 software (SPSS Inc., Chicago, IL, USA), comparisons between groups were made using one-way ANOVA followed by a least significant difference test. All results are presented as the mean ± standard error. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Data quality control and analysis of DEGs

Quality control of the reads was performed and then assembled using Bowtie 1 software. The results are summarized in [Table II](#tII-ol-0-0-8032){ref-type="table"}. With P\<0.01 and \|log~2~ FC\| ≥1 as thresholds, the DEGs between the curcumin and control group were identified by Cufflink software. Compared with the control group, a total of 201 DEGs were identified in the curcumin-treated group, including 114 upregulated and 87 downregulated genes.

### Functional and pathway enrichment analyses

The upregulated genes were significantly enriched in 3 GO terms, including 'biological process' (FDR=3.75×10^−6^), 'cellular component organization' (FDR=1.95×10^−2^) and 'cellular component organization or biogenesis' (FDR=2.08×10^−2^; [Table III](#tIII-ol-0-0-8032){ref-type="table"}). The downregulated genes including hypoxia-inducible factor-1α (HIF1A) were significantly enriched in signal transduction (FDR=1.03×10^−2^), cell communication (FDR=1.89×10^−2^) and cellular process (FDR=5.62×10^−3^; [Table III](#tIII-ol-0-0-8032){ref-type="table"}). In addition, there were no KEGG pathways significantly enriched for the upregulated or downregulated genes. Importantly, the GO term 'biological process' was enriched for upregulated genes \[eukaryotic translation elongation factor 1α1 (EEF1A1), activating transcription factor 7 interacting protein (ATF7IP), SMAD family member 7 (SMAD7), CLTC, minichromosome maintenance 10 (MCM10), ITPR1, WW domain containing E3 ubiquitin protein ligase 2 (WWP2) and ATP synthase, H^+^ transporting, mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1)\], and downregulated genes \[HIF1A and a disintegrin and metalloprotease 15 (ADAM15)\].

### Analysis of PPI network

A total of 39,240 PPI pairs were downloaded from HPRD Release 9. The DEG.PPI network had 929 interactions and 913 node genes, including 73 upregulated, 43 downregulated and 797 genes with no significant change in expression ([Fig. 1](#f1-ol-0-0-8032){ref-type="fig"}). In particular, EEF1A1 (degree=88), ATF7IP (degree=64), HIF1A (degree=44), SMAD7 (degree=43), CLTC (degree=42), MCM10 (degree=28), ITPR1 (degree=27), ADAM15 (degree=24), WWP2 (degree=22) and ATP5C1 (degree=21) exhibited higher degrees in the DEG.PPI network.

### Effects of curcumin treatment on the mRNA levels of EEF1A1, ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1 in U-2 OS cells

The mRNA levels of EEF1A1, ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1, which were the top 10 nodes with higher degrees in the PPI network, were measured. The results of RT-qPCR demonstrated that treatment with curcumin significantly increased the mRNA levels of CLTC and ITPR1 compared with DMSO-treated and control cells (P\<0.01; [Fig. 2](#f2-ol-0-0-8032){ref-type="fig"}). Additionally, the differential expression of ITPR1in curcumin-treated cells was more marked compared with CLTC.

### RNA interference assay of ITPR1

With ITPR1 siRNA sequences, RNA interference assay was performed in U-2 OS cells. Then, the cells were collected for RT-qPCR analysis. The result of RT-qPCR demonstrated that ITPR1 was significantly decreased in cells transferred with ITPR1 siRNA sequences compared with the negative control cells and control cells (P\<0.001; [Fig. 3](#f3-ol-0-0-8032){ref-type="fig"}).

### Effects of curcumin treatment and ITPR1 expression on proliferation in U-2 OS cells

The cell proliferation assay indicated that curcumin treatment was able to significantly suppress the proliferation of U-2 OS cells than the control group not treated with curcumin (P\<0.05; [Fig. 4](#f4-ol-0-0-8032){ref-type="fig"}), and the effect of curcumin-mediated suppression decreased subsequent to ITPR1 knockdown (P\<0.01 vs. negative + curcumin; [Fig. 4](#f4-ol-0-0-8032){ref-type="fig"}).

### Effects of curcumin treatment and ITPR1 expression on apoptosis of U-2 OS cells

Flow cytometry was used to analysis the apoptotic rate of U-2 OS cells, and the results indicated that treatment with curcumin was able to significantly promote apoptosis of U-2 OS cells compared with the control not treated with curcumin (P\<0.05; [Fig. 5](#f5-ol-0-0-8032){ref-type="fig"}), while the apoptotic rate of U-2 OS cells transfected with ITPR1 siRNA sequences was significantly decreased (P\<0.05; [Fig. 5](#f5-ol-0-0-8032){ref-type="fig"}).

### Effects of curcumin treatment and ITPR1 expression on migration of U-2 OS cells

A wound healing assay was performed to detect the migration of U-2 OS cells. The results indicated that treatment with curcumin significantly inhibited cell migration (P\<0.01; [Fig. 6](#f6-ol-0-0-8032){ref-type="fig"}). Compared with the control group, ITPR1 interference promoted migration of U-2 OS cells (P\<0.01; [Fig. 6](#f6-ol-0-0-8032){ref-type="fig"}). Meanwhile, ITPR1 interference significantly promoted migration of U-2 OS cells compared with curcumin-treated cells (P\<0.05; [Fig. 6](#f6-ol-0-0-8032){ref-type="fig"}).

### Effects of curcumin treatment and ITPR1 expression on invasion of U-2 OS cells

Additionally, a Transwell assay was utilized to investigate the effects of curcumin treatment and ITPR1 expression on invasion of U-2 OS cells. The results of the Transwell assay suggested that treatment with curcumin was able to significantly inhibit invasion of U-2 OS cells compared with the control not treated with curcumin (P\<0.05; [Fig. 7](#f7-ol-0-0-8032){ref-type="fig"}). In addition, ITPR1 interference relieved the inhibitory effect of curcumin treatment on cell invasion (P\<0.05; [Fig. 7](#f7-ol-0-0-8032){ref-type="fig"}).

Discussion
==========

In the present study, RNA-sequencing was used to perform transcriptomic analysis of human osteosarcoma U-2 OS cells treated with curcumin or DMSO. A total of 201 DEGs were identified in the curcumin-treated group, including 114 upregulated and 87 downregulated genes. Functional enrichment indicated that downregulated *HIF1A* was involved in biological processes, including signal transduction, cell communication and cellular process. *HIF1A* serves a key role in progression, invasion and metastasis of a number of types of human cancer, including osteosarcoma ([@b29-ol-0-0-8032]). It has been demonstrated that small hairpin RNA (shRNA)-mediated knockdown of *HIF1A* was able to efficiently inhibit the hypoxia transduction pathway and block the growth of osteosarcoma cells ([@b30-ol-0-0-8032]). *HIF1A* functions in osteosarcoma progression and the oxygen-dependent degradation of *HIF1A* may be critical for osteosarcoma ([@b31-ol-0-0-8032]). *HIF1A* is highly relevant to the primary occurrence or recurrence, size, clinical stage, pathological grade and angiogenesis of the osteosarcoma of the jaw, and may serve as a therapeutic target for the disease ([@b32-ol-0-0-8032]). Therefore, the present study hypothesized that *HIF1A* may also be involved in osteosarcoma.

*EEF1A1* is overexpressed in methotrexate-treated osteosarcoma Saos-2 cell line, and may promote cell growth through the increase of protein translation ([@b33-ol-0-0-8032]). Concurrently, the inhibition of *EEF1A1* may protect myotubes from apoptosis ([@b34-ol-0-0-8032]). Blanch *et al* ([@b35-ol-0-0-8032]) revealed that *EEF1A1* exhibited effects on tumor protein (*p*) *53* and *p73* through regulating human homologue of Mdm2 (*HDM2*) in a number of types of cancer, including osteosarcoma ([@b35-ol-0-0-8032]). Furthermore, several studies have demonstrated that the p53-family proteins participate in tumorigenesis via the mediation of the genes associated with cell cycle progression and apoptosis ([@b36-ol-0-0-8032],[@b37-ol-0-0-8032]). In osteosarcoma Saos2 cells, *SMAD7* may suppress bone morphogenetic protein 2 (BMP2)-induced differentiation and BMP/SMAD signaling through interacting with nuclear factor-κB ([@b38-ol-0-0-8032]). Previous studies have reported that *SMAD7* overexpression may inhibit tumor progression and lung metastasis of osteosarcoma ([@b39-ol-0-0-8032],[@b40-ol-0-0-8032]). Taken together, these data suggested that *EEF1A1* and *SMAD7* may participate in osteosarcoma. In the PPI network of the present study, EEF1A1 (degree=88), ATF7IP (degree=64), HIF1A (degree=44), SMAD7 (degree=43), CLTC (degree=42), MCM10 (degree=28), ITPR1 (degree=27), ADAM15 (degree=24), WWP2 (degree=22) and ATP5C1 (degree=21) exhibited the highest degrees. These genes were involved in the GO term 'biological process', indicating that they may be involved in the anticancer role of curcumin in human osteosarcoma U-2 OS cells through biological processes.

To additionally investigate the mechanisms of action of curcumin on human osteosarcoma U-2 OS cells, the mRNA levels of *EEF1A1, ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2* and *ATP5C1* in U-2 OS cells were analyzed. RT-qPCR demonstrated that treatment with curcumin significantly increased the mRNA levels of *CLTC* and *ITPR1* in curcumin-treated cells, while the mRAN levels of *ADAM15* dramatically decreased in curcumin-treated cells. Notably, the differential expression of *ITPR1* was more significant compared with *CLTC*. Then, the effects of curcumin treatment and *ITPR1* expression on proliferation, apoptosis, migration and invasion in U-2 OS cells were investigated. The results indicated that treatment with curcumin was able to significantly promote apoptosis and suppress proliferation, migration and invasion. It was also indicated that *ITPR1* may contribute to the effects mediated by curcumin. A previous study had suggested that curcumin suppressed proliferation, invasion, survival, metastasis and angiogenesis of a number of types of cancer via interacting with cell signaling proteins including enzymes and inflammatory cytokines ([@b41-ol-0-0-8032]). Lee *et al* ([@b42-ol-0-0-8032]) with other previous studies demonstrated that treatment with curcumin promoted G1/S and G2/M cell cycle arrest and that activation of the caspase-3 signaling pathway induced apoptosis in human osteosarcoma cells ([@b14-ol-0-0-8032],[@b43-ol-0-0-8032]). Li *et al* ([@b44-ol-0-0-8032]) indicated that curcumin inhibited proliferation of osteosarcoma via the inactivation of the Notch-1 signaling pathway. The *ITPR1* gene encodes the intracellular calcium release channel type 1 InsP3R that can bind sensitized cells and cytochrome c to apoptotic stimuli ([@b45-ol-0-0-8032]--[@b47-ol-0-0-8032]). In osteoblastic cells, including G-292 osteosarcoma cells, exposure to interleukin-1β, tumor necrosis factor α and other apoptotic stimuli increase mRNA and protein levels of *ITPR1* ([@b48-ol-0-0-8032]). These finding suggest that curcumin may serve an anticancer role in human osteosarcoma U-2 OS cells by regulating *ITPR1*.

In conclusion, a total of 201 DEGs were identified in the curcumin-treated group compared with the control group. Curcumin may serve an anticancer role by regulating apoptosis, proliferation, migration and invasion in human osteosarcoma U-2 OS cells. In addition, *ITPR1* may be involved in the mechanism of action of curcumin treatment of osteosarcoma.

![Protein-protein interaction network that involves the identified differentially expressed genes. Red and green nodes represent upregulated and downregulated genes, respectively. Blue nodes indicate the genes with no significant change in expression.](ol-15-04-5593-g00){#f1-ol-0-0-8032}

![Treatment with curcumin significantly increases the mRNA levels of CLTC and ITPR1 and decreases the mRNA levels of ADAM15 in curcumin-treated cells compared with dimethyl sulfoxide-treated and control cells, \*P\<0.01 compared with control cells, ^\#^P\<0.01 compared with dimethyl sulfoxide-treated cells. EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H^+^ transporting, mitochondrial F1 complex, gamma polypeptide 1; Con, control; DMSO, dimethyl sulfoxide.](ol-15-04-5593-g01){#f2-ol-0-0-8032}

![ITPR1 is significantly decreased in cells transferred with ITPR1 siRNA sequences in comparison with negative control cells and control cells. \*\*\*P\<0.001 when comparing the siRNA group with the negative control and control cells (compared separately). ITPR1, inositol 1,4,5-triphosphate receptor type 1; si, small interfering; con, control.](ol-15-04-5593-g02){#f3-ol-0-0-8032}

![Treatment with curcumin significantly suppresses proliferation of U-2 OS cells, and the effect of curcumin-mediated suppression decreases following knockdown of inositol 1,4,5-triphosphate receptor type 1. \*P\<0.05, compared with negative control cells and control cells; ^\#^P\<0.01, compared with negative and curcumin-treated cells. si, small interfering; con, control.](ol-15-04-5593-g03){#f4-ol-0-0-8032}

![Treatment with curcumin significantly promotes apoptosis of U-2 OS cells, while the apoptotic rate of U-2 OS cells transfected with inositol 1,4,5-triphosphate receptor type 1 siRNA sequences were significantly decreased. \*P\<0.05, compared with negative control cells and control cells; ^\#^P\<0.05, compared with negative and curcumin-treated cells. si, small interfering; con, control.](ol-15-04-5593-g04){#f5-ol-0-0-8032}

![Treatment with curcumin significantly inhibits cell migration, while ITPR1 interference promotes migration of U-2 OS cells (magnification, ×200). \*P\<0.01, compared with negative control cells and control cells (Note: for siRNA treated cells at 12 h, the \*P\<0.01 is compared with control cells); ^\#^P\<0.05, compared with negative and curcumin-treated cells. si, small interfering; con, control. ITPR1, inositol 1,4,5-triphosphate receptor type 1.](ol-15-04-5593-g05){#f6-ol-0-0-8032}

![Treatment with curcumin significantly inhibits invasion of U-2 OS cells, and inositol 1,4,5-triphosphate receptor type 1 interference relieves the inhibitory effect of curcumin on cell invasion (magnification, ×200). \*P\<0.05 compared with negative control cells and control cells; ^\#^P\<0.05 compared with negative and curcumin-treated cells. si, small interfering; con, control.](ol-15-04-5593-g06){#f7-ol-0-0-8032}

###### 

Primer sequences for specific genes.

  Name of primer   Primer sequences (5′-3′)
  ---------------- --------------------------
  EEF1A1-hf        TGCCTGGGTCTTGGATAAAC
  EEF1A1-hr        GCCTGAGATGTCCCTGTAAT
  ATF7IP-hf        TTCCGCCCCAAAAGATTCAGA
  ATF7IP-hr        CTGCTTCAAGTTGCTGACGATC
  HIF1A-hf         ACTTCTGGATGCTGGTGATT
  HIF1A-hr         GTTCAAACTGAGTTAATCCC
  SMAD7-hf         ACCTTAGCCGACTCTGCGAACT
  SMAD7-hr         TTTCAGCGGAGGAAGGCACA
  CLTC-hf          TTGAATACGGTTGCTCTTGT
  CLTC-hr          ATGCCAGTCAGAAGTAACCA
  MCM10-hf         CTTTGAATACGGTTGCTCTT
  MCM10-hr         GTACGGTAATTGATAATCTGG
  ITPR1-hf         CCTGGTTGATGATCGTTGTGTT
  ITPR1-hr         GCTTTTGGGCAGAGTAGCGGTT
  ADAM15-hf        ATCCCTGCTGTGATTCTTTGACC
  ADAM15-hr        TGGGCATAGGAGGCACAACG
  WWP2-hf          CCCCGAATCCCAACACGACT
  WWP2-hr          TCCCATCCAGCAGGCAGAGC
  ATP5C1-hf        AAAAGCGAGGTTGCTACACT
  ATP5C1-hr        ATGACTGACGCATCTCCAAA
  GAPDH-hf         TGACAACTTTGGTATCGTGGAAGG
  GAPDH-hr         AGGCAGGGATGATGTTCTGGAGAG

EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease domain 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; h, human; f, forward; r, reverse.

###### 

Results from quality control and assembly of sequencing data.

  ID         Group      Number of cleaned paired-end reads   Number of aligned pair reads
  ---------- ---------- ------------------------------------ ------------------------------
  14710C-1   Control    11,660,638                           8,129,145
  14710C-2   Control    12,351,701                           8,531,536
  14710C-5   Curcumin   13,820,514                           8,368,710
  14710C-6   Curcumin   11,927,581                           8,797,461

###### 

GO terms enriched for upregulated and downregulated genes.

  Go term              Description                                     Gene number   FDR         Gene symbol
  -------------------- ----------------------------------------------- ------------- ----------- ----------------------------------------------
  Upregulated DEGs                                                                               
    GO: 8150           Biological process                              94            3.75×10-6   EEF1A1, ATF7IP, SMAD7, CLTC, MCM10
    GO: 16043          Cellular component organization                 41            1.95×10-2   ATF7IP, SMAD7, CLTC, CDH4, RTN3
    GO: 71840          Cellular component organization or biogenesis   41            2.08×10-2   ATF7IP, SMAD7, CLTC, CDH4, RTN3
  Downregulated DEGs                                                                             
    GO: 8150           Biological process                              64            8.18×10-4   HIF1A, ADAM15, ARFRP1, AKAP9, ABI2
    GO: 50896          Response to stimulus                            40            5.62×10-3   HIF1A, ADAM15, ARFRP1, AKAP9, MALT1
    GO: 51716          Cellular response to stimulus                   34            5.62×10-3   HIF1A, ARFRP1, AKAP9, MALT1, MGLL
    GO: 9987           Cellular process                                59            5.62×10-3   HIF1A, ADAM15, ARFRP1,RBM5, PFDN6
    GO: 7165           Signal transduction                             29            1.03×10-2   HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
    GO: 23052          Signaling                                       30            1.79×10-2   HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
    GO: 44700          Single organism signaling                       30            1.79×10-2   HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
    GO: 7154           Cell communication                              30            1.89×10-2   HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
    GO: 71704          Organic substance metabolic process             46            1.89×10-2   HIF1A, ADAM15, ARFRP1,GSTO2, ADK
    GO: 44238          Primary metabolic process                       45            1.89×10-2   HIF1A, ADAM15, ARFRP1,GSTO2, ADK
    GO: 50789          Regulation of biological process                43            2.04×10-2   HIF1A, ARFRP1, AKAP9, ABI2, RBM5
    GO: 50794          Regulation of cellular process                  41            2.55×10-2   HIF1A, ARFRP1, AKAP9, ABI2, RBM5
    GO: 44699          Single-organism process                         53            2.98×10-2   HIF1A, ADAM15, ARFRP1, AKAP9, ABI2
    GO: 1568           Blood vessel development                          6           4.65×10-2   HIF1A, ADAM15, ANKRD17, RAPGEF1, NPRL3, NRP1
    GO: 43170          Macromolecule metabolic process                 38            4.98×10-2   HIF1A, ADAM15, ABI2, RBM5, PFDN6

GO, Gene Ontology; DEGs, differentially expressed genes; FDR: false discovery rate; EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease domain 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; RTN3, reticulon 3; GSTO2, glutathione S-transferase Omega 2; ADK, adenosine kinase; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; RAP1GAP2, RAP1 GTPase activating protein 2; AKAP9, A-kinase anchoring protein 9; MGLL, monoglyceride lipase; PFDN6, prefoldin subunit 6; RBM5, RNA binding motif protein 5; ABI2, Abl interactor 2; NRP1, neuropilin 1; NPRL3, nitrogen permease regulator 3-like protein 3.
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